Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...

One scam making the rounds recently exploits a common anxiety of many drivers: passing through tolls without paying. If you want to avoid falling for the FasTrak scheme, here’s everything you ...

Consumers planning to spend big this Valentine's Day should be aware of scams. Romance scams target vulnerable people by building trust and then asking for money. Fake websites and florists may ...

Thailand cut electricity supplies on Wednesday to several areas in neighboring Myanmar that are home to sites at the center of a global, billion-dollar online scam industry. As of Wednesday ...

Now referred to as the EZDriveMa scam, the messages aren’t real and no money is owed. And for area drivers, the tipoff is in the name; EZDriveMa is not E-ZPass. But, that’s not stopping scammers.

AS THE CEO of a small bank in Kansas, a former chairman of the Kansas Bankers Association and a former officer of the American Bankers Association, Shan Hanes knew all about the risks of online fraud.

The new year doesn't necessarily bring about a shift in scam tactics. In fact, over the years, many scams have slowly evolved as scammers incorporate new technology and play off of the most recent ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...